Can treatment adverse events be optimized by switching between different sphingosine 1-phosphate receptor modulators in multiple sclerosis? A case series-Reference-Cited by-同舟云学术

Can treatment adverse events be optimized by switching between different sphingosine 1-phosphate receptor modulators in multiple sclerosis? A case series

Published:2024-04-02 Issue:6 Volume:271 Page:3678-3681
ISSN:0340-5354
Container-title:Journal of Neurology
language:en
Short-container-title:J Neurol

Author:

Guerrieri Simone,Rubin Martina,Gattuso Irene,Zanetta Chiara,Genchi Angela,Preziosa Paolo,Rocca Maria Assunta,Filippi Massimo^ORCID,Moiola Lucia

Publisher

Springer Science and Business Media LLC

Link

https://link.springer.com/content/pdf/10.1007/s00415-024-12342-z.pdf

Reference10 articles.

1. Dumitrescu L, Papathanasiou A, Coclitu C et al (2023) An update on the use of sphingosine 1-phosphate receptor modulators for the treatment of relapsing multiple sclerosis. Expert Opin Pharmacother 24:495–509

2. Aoki M, Aoki H, Ramanathan R, Hait NC, Takabe K (2016) Sphingosine-1-phosphate signaling in immune cells and inflammation: roles and therapeutic potential. Mediators Inflamm 2016:8606878

3. Jana A, Pahan K (2010) Sphingolipids in multiple sclerosis. NeuroMol Med 12:351–361

4. Chun J, Giovannoni G, Hunter SF (2021) Sphingosine 1-phosphate receptor modulator therapy for multiple sclerosis: differential downstream receptor signalling and clinical profile effects. Drugs 81:207–231

5. Fischer S, Proschmann U, Akgün K, Ziemssen T (2021) Lymphocyte counts and multiple sclerosis therapeutics: between mechanisms of action and treatment-limiting side effects. Cells 10:3177

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Fingolimod/ozanimod;Reactions Weekly;2024-09-07